<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>SUMMARYâ€‚ For the past 40 years, beta-blockers have been widely used in cardiovascular medicine, reducing morbidity as well as mortality </plain></SENT>
<SENT sid="1" pm="."><plain>Beta-blockers are currently used in a number of cardiovascular conditions such as systolic <z:hpo ids='HP_0001635'>heart failure</z:hpo>, postmyocardial infarction, and in prevention and treatment of <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>They are not recommended as the first line <z:chebi fb="0" ids="35674">antihypertensive</z:chebi> therapy, particularly in the elderly, unless there are specific indications </plain></SENT>
<SENT sid="3" pm="."><plain>Despite the benefits of beta-blockers, tolerability concerns in patients with co-morbidities have limited their use </plain></SENT>
<SENT sid="4" pm="."><plain>Some of these problems were overcome with the discovery of cardioselective beta-blockers </plain></SENT>
<SENT sid="5" pm="."><plain>The third generation beta-blockers have additional properties of vasodilatation and advantages in terms of minimizing the adverse effects of beta-blockers </plain></SENT>
<SENT sid="6" pm="."><plain>Some of the advantages include improvement of <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, decrease in cholesterol as well as alleviation of <z:hpo ids='HP_0000802'>erectile dysfunction</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0011009'>Acute</z:hpo> treatment with beta-blockers modifies local muscular metabolic properties and impairs endurance exercise capacity whereas the influence of <z:hpo ids='HP_0011010'>chronic</z:hpo> is debated controversially </plain></SENT>
</text></document>